Headlines about Immunomedics (NASDAQ:IMMU) have been trending somewhat positive on Saturday, Alpha One Sentiment reports. Alpha One, a division of Accern, ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immunomedics earned a news impact score of 0.11 on Alpha One’s scale. Alpha One also assigned press coverage about the biopharmaceutical company an impact score of 50 out of 100, indicating that recent media coverage is somewhat likely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected AlphaOne’s analysis:
- School yearbook to be reissued with pro-Trump photos (upbeacon.net)
- Learn details of the global hepatocellular carcinoma drugs pipeline developement therapeutics (whatech.com)
- Amazon buying Whole Foods for $13.7billion (upbeacon.net)
- ETFs with exposure to Immunomedics, Inc. : June 16, 2017 (finance.yahoo.com)
- Ultra-Powerful Xbox One X Unveiled (healthcaremenu.net)
A number of equities research analysts have issued reports on IMMU shares. Wells Fargo & Company raised shares of Immunomedics from a “market perform” rating to an “outperform” rating in a research note on Friday, May 5th. Jefferies Group LLC set a $8.00 target price on shares of Immunomedics and gave the company a “buy” rating in a research note on Thursday, March 16th. Cowen and Company started coverage on shares of Immunomedics in a research note on Friday, May 26th. They set an “outperform” rating for the company. Finally, ValuEngine raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $5.88.
Immunomedics (IMMU) traded down 2.98% on Friday, hitting $7.48. 3,976,128 shares of the stock were exchanged. The stock’s market capitalization is $819.84 million. Immunomedics has a one year low of $1.95 and a one year high of $8.44. The company has a 50 day moving average of $7.20 and a 200 day moving average of $5.46.
COPYRIGHT VIOLATION NOTICE: “Immunomedics (IMMU) Getting Somewhat Positive Press Coverage, Analysis Shows” was first reported by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.wkrb13.com/markets/2230957/immunomedics-immu-getting-somewhat-positive-press-coverage-analysis-shows.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230957/immunomedics-immu-getting-somewhat-positive-press-coverage-analysis-shows.html
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.